Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
9.53 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Assets: | |||||
| Current Assets: | |||||
| Cash & Cash Equivalents
| 128.101 | 54.912 | 346.071 | 41.699 | 5.995 |
| Short Term Investments
| 104.312 | 207.914 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 232.413 | 262.826 | 346.071 | 41.699 | 5.995 |
| Net Receivables
| 0.505 | 7.656 | 0 | 0 | 0 |
| Inventory
| 0 | 0.96 | 0 | 0 | 0 |
| Other Current Assets
| 3.294 | 4.444 | 2.595 | 1.892 | 0.514 |
| Total Current Assets
| 236.212 | 275.886 | 348.666 | 43.591 | 9.759 |
| Non-Current Assets: | |||||
| Property, Plant & Equipment, Net
| 62.611 | 61.907 | 12.325 | 4.623 | 1.335 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 4.58 | 4.318 | 5.338 | 1.164 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.352 | 0.278 | 0 | 0 | 0 |
| Total Non-Current Assets
| 67.543 | 66.503 | 17.663 | 5.787 | 1.335 |
| Total Assets
| 303.755 | 342.389 | 366.329 | 49.378 | 11.094 |
| Liabilities & Equity: | |||||
| Current Liabilities: | |||||
| Account Payables
| 11.152 | 7.862 | 6.558 | 7.066 | 3.195 |
| Short Term Debt
| 3.162 | 3.127 | 0 | 0 | 0.75 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 17.678 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 14.6 | 14.58 | 10.08 | 22.209 | 0.347 |
| Total Current Liabilities
| 46.592 | 25.569 | 16.638 | 29.275 | 4.292 |
| Non-Current Liabilities: | |||||
| Long Term Debt
| 42.877 | 43.874 | 0 | 67.764 | 18.95 |
| Deferred Revenue Non-Current
| 32.323 | 0 | 0 | 1.067 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 2.713 | 1.533 | 2.176 | 0 | 0 |
| Total Non-Current Liabilities
| 77.913 | 45.407 | 2.176 | 68.831 | 18.95 |
| Total Liabilities
| 124.505 | 70.976 | 18.814 | 98.106 | 23.242 |
| Equity: | |||||
| Preferred Stock
| 0 | 0 | 366.329 | 0.068 | 0.019 |
| Common Stock
| 0.005 | 0.005 | 0.005 | 0.001 | 0.05 |
| Retained Earnings
| -365.888 | -230.536 | -122.035 | -48.077 | -12.198 |
| Accumulated Other Comprehensive Income/Loss
| -2.724 | -1.752 | -2.021 | -1.056 | -0.069 |
| Other Total Stockholders Equity
| 547.857 | 503.696 | 105.237 | 0.336 | 0.05 |
| Total Shareholders Equity
| 179.25 | 271.413 | 347.515 | -48.728 | -12.148 |
| Total Equity
| 179.25 | 271.413 | 347.515 | -48.728 | -12.148 |
| Total Liabilities & Shareholders Equity
| 303.755 | 342.389 | 366.329 | 49.378 | 11.094 |